The activating mutation on codon W515 of MPL gene is seen in 5-10% of ET and PMF patients who are negative for JAK2 (V617F) (87). Patients that are JAK2wild  and CALRwild , but harboring ET or PMF clinical features should be screened for MPL mutation. This evidence concerns the gene JAK2 and essential thrombocythemia.